

Attorney Docket No. 1877.1001

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re F	Patent Applica	ation of:		
Tai-W	ha CHUNG e	et al.		
Applic	ation No.: 10	0/540,848	Group Art Unit: 1641	
Confir	mation No. 2	217		
Filed:	March 29, 2	006	Examiner: Bao Thuy L. NGUYEN	
For:	METHOD F	OR DIAGNOSING LIVER DISE	ASES (as amended)	
		INFORMATION DISCLOS	SURE STATEMENT	
PO Bo	nissioner for F ox 1450 ndria, VA 223			
subjed	ed certain inf ct U.S. patent deemed mate	ormation which the Examiner ma		the
	1a.	Application publications. English language copy of a coror a PCT International Search English language translation (cattached to non-English languater PTO-1449. Explanations of Relevancy of Providing a concise explanation List of Copending Applications	complete, Abstract or relevant portion(s)) age publications as indicated on the attach References (ATTACHMENT 1(e), hereto) for n of non-English publications.	ed
2. [	This Infor  2a. ☐  2b. ☐  2c. ☐  2d. ☐	(Check either Item 2a Within three months of the filing Within three months of the date § 1.491 in an international appl Before the mailing of a first Off	g date of a national application; e of entry of the national stage as set forth lication. ice Action on the merits; or ice Action after the filing of a Request for	180.00 OP

Serial No.: 10/540,848

3.	specified Action un	rmation Disclosure Statement is filed under 37 CFR § 1.97(c) after the period in paragraph 2 above but before the mailing date of any of a Final Office der § 1.113, a Notice of Allowance under § 1.311 or an action that otherwise osecution in the application, AND	
		(Check either Item 3a or 3b; Item 3b to be checked if any reference known for more than 3 months)	
	3a.	The § 1.97(e) Statement in Item 5 below is applicable; OR The \$180.00 fee set forth in 37 CFR § 1.17(p) is:  enclosed.	
		to be charged to Deposit Account No. 19-3935.	
4.		mation Disclosure Statement is filed under 37 CFR § 1.97(d) after the period in paragraph 3 above, but on or before payment of the Issue Fee, AND	
	4a.	The § 1.97(e) Statement in Item 5 below is applicable; AND The \$180.00 fee set forth in 37 CFR § 1.17(p) is:  enclosed.	
		to be charged to Deposit Account No. 19-3935.	
5.	Statement under § 1.97(e) (applicable if Item 3a or Item 4a is checked)  (Check either Item 5a or 5b)		
	5a. 🗌	In accordance with 37 CFR § 1.97(e)(1), it is stated that each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement.	
	5b.	In accordance with 37 CFR § 1.97(e)(2), it is stated that no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in this Information Disclosure Statement was known by any individual designated in § 1.56(c) more than three months prior to the filing of this Information Disclosure Statement.	
6.	This is a 1.53(b).	continuation/divisional/continuation-in-part application under 37 CFR §	
		(Check appropriate Items 6a and/or 6b)	
	6a. 🗌	Copies of the publications listed on the attached Form PTO-1449 which were previously cited in prior application Serial No, filed on, and which is relied on for an earlier effective filing date for the subject application under 35 U.S.C. § 120, have been omitted pursuant to 37 CFR § 1.98(d).	
	6b. 🗌	Copies of the publications listed on the attached Form PTO-1449 which were not previously cited in prior application Serial No, filed on, and which is relied on for an earlier effective filing date for the subject application under 35 U.S.C. § 120, are provided berewith	

Serial No.: 10/540,848

7.		This is a Request for Continued Examination under 37 CFR § 1.114.		
			(Check either Item 7a or 7b)	
		7a.	The Issue Fee has not been paid. A Petition to Withdraw from issue under 37 CFR § 1.313(c) is filed concurrently herewith or has been granted. A Request for Continued Examination under 37 CFR § 1.114, after payment of the Issue Fee, is proper in accordance with 37 CFR § 1.114(a), respectively.	
8.		This is a	Supplemental Information Disclosure Statement.	
			(Check either Item 8a or 8b)	
		8a. 🗌	This Supplemental Information Disclosure Statement under 37 CFR § 1.97(f) supplements the Information Disclosure Statement filed on A bona fide attempt was made to comply with 37 CFR § 1.98, but inadvertent omissions were made. These omissions have been corrected herein. Accordingly, additional time is requested so that this Supplemental IDS can be considered as if properly filed on	
		8b. 🗌	This Supplemental Information Disclosure Statement is timely filed within one (1) month of the Notice under 37 CFR §§ 1.97 and 1.98, mailed	
9.	9. In accordance with 37 CFR § 1.98, a concise explanation of what is presently understood to be the relevance of each non-English language publication is:  (Check appropriate Items 9a, 9b, 9c and/or 9d)			
		9a.	satisfied for the non-English language publication(s) cited on the enclosed "English language version of the search report or action which indicates the degree of relevance found by the foreign office". (See MPEP § 609, Minimum Requirements for an Information Disclosure Statement, Part A(3): Concise Explanation of Relevance, 8th Ed., Rev. 2) set forth in the application. satisfied for the non-English language publication(s) indicated on the attached Form PTO-1449 as having an English language translation (complete or relevant portion(s)) attached thereto.	
		9d. 🗌	enclosed as Attachment 1(e), hereto.	
10.	be se	, material arch repo	on is made that the information cited in this Statement is, or is considered to to patentability nor a representation that a search has been made (other than rt(s) from a counterpart foreign application or a PCT International Search ibmitted herewith). 37 CFR §§ 1.97(a) and (h).	

Serial No.: 10/540,848

11. The Commissioner is authorized to credit any overpayment or charge any additional fee required under 37 CFR § 1.17 for this Information Disclosure Statement to Deposit Account No. 19-3935.

Respectfully submitted,

STAAS & HALSEY LLP

Registration No. 34,257

Dated: Work Ave., N.W., 7th Floor

Washington, D.C. 20005 Telephone: (202) 434-1500 Facsimile: (202) 434-1501

©2005 Staas & Halsey LLP